What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Immunology, Immunotherapy, Prostate cancer, Internal medicine and Antigen.
As part of one scientific family, he deals mainly with the area of Immunology, narrowing it down to issues related to the Cytotoxic T cell, and often Survival analysis and Tremelimumab.
His Immunotherapy study combines topics in areas such as Bevacizumab, CTL*, Immune tolerance and Immunogenicity.
The concepts of his Prostate cancer study are interwoven with issues in Prostate and Urology.
His Internal medicine research incorporates themes from Gastroenterology and Oncology.
His biological study focuses on CD8.
His most cited work include:
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (1345 citations)
- Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. (1056 citations)
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. (1019 citations)
What are the main themes of his work throughout his whole career to date?
Lawrence Fong mainly focuses on Internal medicine, Oncology, Prostate cancer, Cancer research and Immunology.
His is involved in several facets of Internal medicine study, as is seen by his studies on Cancer, Clinical trial, Pembrolizumab, Phases of clinical research and Chemotherapy.
Lawrence Fong interconnects Ipilimumab, Docetaxel and Atezolizumab in the investigation of issues within Oncology.
His work deals with themes such as Prostate and Immunotherapy, which intersect with Prostate cancer.
He has researched Cancer research in several fields, including Cell, Blockade and CD8, Immune system.
Lawrence Fong regularly links together related areas like Cytotoxic T cell in his Immunology studies.
He most often published in these fields:
- Internal medicine (45.29%)
- Oncology (39.86%)
- Prostate cancer (38.41%)
What were the highlights of his more recent work (between 2019-2021)?
- Cancer research (30.80%)
- Prostate cancer (38.41%)
- Internal medicine (45.29%)
In recent papers he was focusing on the following fields of study:
Lawrence Fong mainly investigates Cancer research, Prostate cancer, Internal medicine, Oncology and Immune system.
The various areas that he examines in his Cancer research study include Cancer, Immune checkpoint inhibitors, Immunotherapy and Antibody.
The Immunotherapy study which covers Antigen that intersects with Docetaxel.
His research in Prostate cancer intersects with topics in Clinical trial and Ipilimumab.
As part of his studies on Internal medicine, Lawrence Fong often connects relevant subjects like Melanoma.
His Sipuleucel-T research focuses on Immunology and how it connects with breakpoint cluster region.
Between 2019 and 2021, his most popular works were:
- Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. (57 citations)
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer (56 citations)
- Tissue Determinants of Human NK Cell Development, Function, and Residence (44 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Cancer research, Immune system, Prostate cancer, Oncology and Internal medicine.
His studies deal with areas such as Cancer, CD8, Receptor, Cytotoxic T cell and Regulation of gene expression as well as Cancer research.
His studies in CD8 integrate themes in fields like Bladder cancer and T cell.
His biological study spans a wide range of topics, including Interleukin 12 and Antigen.
Lawrence Fong has included themes like CTLA-4, Clinical endpoint, Atezolizumab and Adenocarcinoma in his Prostate cancer study.
His Oncology study integrates concerns from other disciplines, such as Discontinuation, Adverse effect, Clinical trial and Melanoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
